44th Annual J.P. Morgan Healthcare Conference
Logotype for Ingersoll Rand Inc

Ingersoll Rand (IR) 44th Annual J.P. Morgan Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Ingersoll Rand Inc

44th Annual J.P. Morgan Healthcare Conference summary

15 Nov, 2026

Financial profile and market performance

  • LTM Q3 2025 revenue was ~$7.5B, adjusted EBITDA ~$2.0B, adjusted EBITDA margin ~27%, and free cash flow ~$1.3B; free cash flow margin was ~20%.

  • Reported revenue was $7.5B, with a 27% EBITDA margin and 17% free cash flow margin; market capitalization was $34B.

  • Revenue grew at ~8% CAGR and adjusted diluted EPS at ~11% CAGR from 2022 through LTM Q3 2025.

  • Since the May 2017 IPO, share price appreciation was ~328%, outperforming the S&P 500 by ~13,500 bps; market-cap value creation was ~$30B through Jan. 9, 2026.

  • Total shareholder return exceeded 330% since 2017, with double-digit EPS CAGR despite industry headwinds; aftermarket consumables represent 37% of revenue.

Strategy and M&A

  • IRX improved EBITDA margins by 600+ bps over five years; IRX and demand generation are expected to support above-market growth.

  • Completed 76 acquisitions since March 2020, including 16 bolt-ons in 2025 at an average pre-synergy purchase multiple of ~9x EBITDA.

  • M&A flywheel supports annual bolt-ons, with multiples reduced post-integration; four life science deals in the past year averaged 10x EBITDA and target mid-teens ROIC within three years.

  • Active pipeline includes ~100 companies, with 10 in active discussions at any time; deals are selected for strategic fit, unique capabilities, and value creation.

  • Life science additions include Leadfluid, Dave Barry Plastics, and Sheridan Mold & Engineering in 2025, and scinomix in January 2026; ILC Dover provided a platform for bolt-ons.

Life science platform and growth

  • Life Science Technologies covers flow control, biopharma and pharma, and medical device solutions, including pumps, containment, material handling, and contract device manufacturing.

  • Estimated life sciences revenue mix rose from 4% in 2020 to 18% in 2024; brands include ILC Dover and Flexan.

  • 85% of life science revenue comes from recurring consumables; highly specified products are integrated into customer applications.

  • Positioned in weight-loss therapies, oncology, minimally invasive procedures, diagnostics, and antibody drug conjugates, which are expected to grow at a mid-teens rate.

  • Global footprint spans North America and Europe, with growing presence in Asia; solutions cover small-molecule API workflows from containment and transfer to temperature control, drying, and packaging.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Ingersoll Rand